Security
BioXcel Therapeutics, Inc. Common Stock · BTAI
BTAINASDAQCommon stockHistorical · closed Sep 4, 2026CIK 1720893Updated Nov 2, 2026
Current security for this SEC filerBTAIQ · OTC
BTAI price & chart
Historical security
This listing closed Sep 4, 2026. Live provider charts are shown only for current listings.
Current security: BTAIQ
About the company
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.
In the news
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering ↗
Recent filings
Completion of Acquisition or Disposition of Assets · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 2.01, 5.02, 5.03, 9.01
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 2.03, 3.01
Entry into a Material Definitive Agreement · Bankruptcy or Receivership
Items 1.01, 1.03
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Show 5 more recent filings
10-Q filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 44,792,000Source | 48,892,000Source | 28,799,000Source | 25,789,000Source | 65,435,000Source | 34,025,000Source | 38,566,000Source | 82,323,000Source | 44,916,000Source | 38,338,000Source | 73,702,000Source | 205,853,000Source |
| Property, Plant and Equipment, NetUSD | 249,000Source | 552,000Source | 99,000Source | 324,000Source | 629,000Source | 117,000Source | 399,000Source | 706,000Source | 175,000Source | 475,000Source | 784,000Source | 1,084,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 36,176,000Source | 40,387,000Source | 12,841,000Source | 17,435,000Source | 56,271,000Source | 17,180,000Source | 31,013,000Source | 74,141,000Source | 28,415,000Source | 29,854,000Source | 65,221,000Source | 193,725,000Source |
| Inventory, NetUSD | 459,000Source | 1,525,000Source | 483,000Source | 506,000Source | 2,680,000Source | 500,000Source | 642,000Source | 2,439,000Source | 722,000Source | 679,000Source | 1,991,000Source | 1,985,000Source |
| Assets, CurrentUSD | 44,403,000Source | 47,792,000Source | 28,700,000Source | 25,243,000Source | 64,181,000Source | 33,908,000Source | 37,777,000Source | 80,917,000Source | 44,685,000Source | 37,394,000Source | 72,143,000Source | 202,868,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,690,000Source | 4,479,000Source | 3,074,000Source | 5,150,000Source | 2,775,000Source | 3,945,000Source | 4,737,000Source | 2,103,000Source | 4,028,000Source | 5,290,000Source | 2,782,000Source | 3,067,000Source |
| Operating Lease, Right-of-Use AssetUSD | 140,000Source | 461,000Source | 0Source | 222,000Source | 538,000Source | 0Source | 303,000Source | 613,000Source | 56,000Source | 382,000Source | 688,000Source | 976,000Source |
| Other Assets, NoncurrentUSD | 0Source | 87,000Source | — | — | 87,000Source | — | 87,000Source | 87,000Source | 0Source | 87,000Source | 87,000Source | 925,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 133,711,000Source | 134,525,000Source | 144,259,000Source | 133,456,000Source | 139,736,000Source | 139,568,000Source | 128,738,000Source | 154,686,000Source | 140,379,000Source | 131,439,000Source | 130,210,000Source | 129,078,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | — | — | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 73,000Source | 42,000Source | 31,000Source | 60,000Source | 40,000Source | 27,000Source | 59,000Source | 34,000Source | 76,000Source | 49,000Source | 30,000Source | 28,000Source |
| Additional Paid in CapitalUSD | 618,557,000Source | 553,663,000Source | 632,007,000Source | 568,911,000Source | 551,347,000Source | 627,215,000Source | 567,220,000Source | 544,992,000Source | 624,555,000Source | 557,047,000Source | 534,060,000Source | 488,292,000Source |
| Retained Earnings (Accumulated Deficit)USD | -707,549,000Source | -639,338,000Source | -747,498,000Source | -676,638,000Source | -625,688,000Source | -732,785,000Source | -657,451,000Source | -617,389,000Source | -720,094,000Source | -650,197,000Source | -590,598,000Source | -411,545,000Source |
| Stockholders' Equity Attributable to ParentUSD | -88,919,000Source | -85,633,000Source | -115,460,000Source | -107,667,000Source | -74,301,000Source | -105,543,000Source | -90,172,000Source | -72,363,000Source | -95,463,000Source | -93,101,000Source | -56,508,000Source | 76,775,000Source |
| Liabilities and EquityUSD | 44,792,000Source | 48,892,000Source | 28,799,000Source | 25,789,000Source | 65,435,000Source | 34,025,000Source | 38,566,000Source | 82,323,000Source | 44,916,000Source | 38,338,000Source | 73,702,000Source | 205,853,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 37,804,000Source | 25,557,000Source | 137,149,000Source | 33,376,000Source | 27,288,000Source | 54,994,000Source | 25,546,000Source | 31,481,000Source | 53,926,000Source | 22,233,000Source | 27,267,000Source | 32,898,000Source |
| Operating Lease, Liability, CurrentUSD | 161,000Source | 368,000Source | — | 256,000Source | 361,000Source | — | 350,000Source | 353,000Source | 65,000Source | 374,000Source | 346,000Source | 319,000Source |
| Accounts Payable, CurrentUSD | 16,276,000Source | 14,889,000Source | 18,783,000Source | 16,692,000Source | 13,256,000Source | 16,247,000Source | 15,450,000Source | 17,220,000Source | 14,701,000Source | 15,990,000Source | 13,654,000Source | 10,228,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 161,000Source | — | — | 256,000Source | — | — | 350,000Source | 0Source | 65,000Source | 440,000Source | 786,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 4,363,000Source | 10,193,000Source | 3,921,000Source | 5,090,000Source | 13,485,000Source | 6,388,000Source | 3,986,000Source | 13,675,000Source | 4,341,000Source | 5,762,000Source | 12,424,000Source | 18,669,000Source |
| Long-term Debt, Current MaturitiesUSD | 16,823,000Source | — | 104,451,000Source | 11,216,000Source | — | 22,431,000Source | 5,608,000Source | — | 24,931,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 92,302,000Source | 104,440,000Source | 0Source | 97,469,000Source | 103,006,000Source | 77,858,000Source | 99,918,000Source | 101,633,000Source | 84,663,000Source | 102,508,000Source | 100,598,000Source | 93,051,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -12,691,000Source | -7,254,000Source | -69,897,000Source | -59,599,000Source | -179,053,000Source | -165,757,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 435,000Source | 180,000Source | 2,767,000Source | 6,156,000Source | 18,614,000Source | 17,337,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -222,000Source | -37,000Source | 43,000Source | -1,312,000Source | 6,000Source | 1,985,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -11,809,000Source | -12,043,000Source | -57,615,000Source | -72,027,000Source | -155,006,000Source | -135,341,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | -20,000Source | -139,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | 20,000Source | 139,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 0Source | 1,000Source | 17,000Source | 54,000Source | 27,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 232,000Source | 13,202,000Source | 56,518,000Source | 36,660,000Source | 26,522,000Source | 96,237,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 8,108,000Source | 0Source | 0Source | 2,500,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -11,577,000Source | 1,159,000Source | -1,097,000Source | -35,367,000Source | -128,504,000Source | -39,243,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 37,320,000Source | 40,387,000Source | 13,801,000Source | 18,575,000Source | 17,180,000Source | 31,013,000Source | 28,757,000Source | 29,854,000Source | 65,221,000Source | 193,725,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 3,645,000Source | 0Source | 9,690,000Source | 7,968,000Source | 7,551,000Source | 2,697,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 581,000Source | 1,865,000Source | 358,000Source | 1,556,000Source | 435,000Source | 180,000Source | 2,767,000Source | 6,156,000Source | 18,614,000Source | 17,337,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | 441,000Source | 106,000Source | 774,000Source | 393,000Source | 502,000Source | 350,000Source | 1,652,000Source | 467,000Source | 1,373,000Source | 860,000Source |
| DepreciationUSD | — | — | 75,000Source | 77,000Source | 18,000Source | 75,000Source | 58,000Source | 76,000Source | 300,000Source | 309,000Source | 318,000Source | 327,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | 1,519,000Source | 6,559,000Source | -3,505,000Source | 20,180,000Source | 438,000Source | -389,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | -3,505,000Source | 20,181,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | -2,000Source | -22,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | 4,373,000Source | 3,790,000Source | 4,257,000Source | 4,222,000Source | 4,198,000Source | 3,993,000Source | 16,984,000Source | 15,129,000Source | — | — |
| Inventory Write-downUSD | — | — | 0Source | 1,157,000Source | 0Source | 95,000Source | 265,000Source | 0Source | 108,000Source | 1,980,000Source | — | — |
| Investment Income, InterestUSD | — | — | 236,000Source | 616,000Source | 131,000Source | 230,000Source | 211,000Source | 279,000Source | 1,066,000Source | 2,602,000Source | 5,649,000Source | 2,528,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -30,911,000Source | -13,650,000Source | -14,713,000Source | -19,187,000Source | -12,691,000Source | -7,254,000Source | -69,897,000Source | -59,599,000Source | -179,053,000Source | -165,757,000Source |
| Operating Lease, ExpenseUSD | — | — | 104,000Source | 101,000Source | 101,000Source | 101,000Source | 103,000Source | 101,000Source | 410,000Source | 394,000Source | 392,000Source | 410,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -12,546,000Source | 4,817,000Source | -394,000Source | 657,000Source | 1,519,000Source | 6,559,000Source | -3,518,000Source | 20,173,000Source | 394,000Source | -427,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 27,032,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 98,600,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 508,000Source | 283,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 98,000Source | 214,000Source | 182,000Source | 120,000Source | 206,000Source | 168,000Source | 642,000Source | 2,266,000Source | 1,380,000Source | 375,000Source |
| Cost of RevenueUSD | — | — | 11,000Source | 1,170,000Source | 22,000Source | 107,000Source | 283,000Source | 14,000Source | 164,000Source | 2,143,000Source | 1,260,000Source | 20,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 5,381,000Source | 7,683,000Source | 7,189,000Source | 5,609,000Source | 7,191,000Source | 5,699,000Source | 20,494,000Source | 34,492,000Source | 83,413,000Source | 68,761,000Source |
| Operating Income (Loss)USD | — | — | -14,228,000Source | -15,293,000Source | -10,193,000Source | -15,852,000Source | -10,223,000Source | -10,099,000Source | -50,461,000Source | -67,245,000Source | -171,782,000Source | -159,645,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -12,546,000Source | 4,817,000Source | -394,000Source | 657,000Source | 1,519,000Source | 6,559,000Source | -3,518,000Source | 20,173,000Source | 394,000Source | -427,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -30,911,000Source | -13,650,000Source | -14,713,000Source | -19,187,000Source | -12,691,000Source | -7,254,000Source | -69,897,000Source | -59,599,000Source | -179,053,000Source | -165,757,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.18Source | -5.15Source | -0.49Source | -2.45Source | -0.54Source | -1.5Source | -5.73Source | -23.51Source | -6.15Source | -5.92Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.18Source | -5.15Source | -0.49Source | -2.45Source | -0.54Source | -1.5Source | -5.73Source | -23.51Source | -6.15Source | -5.92Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 14,196,000Source | 2,649,000Source | 30,300,000Source | 7,843,000Source | 23,571,000Source | 4,834,000Source | 12,208,000Source | 2,535,000Source | 29,129,000Source | 28,015,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 14,196,000Source | 2,649,000Source | 30,300,000Source | 7,843,000Source | 23,571,000Source | 4,834,000Source | 12,208,000Source | 2,535,000Source | 29,129,000Source | 28,015,000Source |
| Interest Expense (non-operating)USD | — | — | 4,373,000Source | 3,790,000Source | 4,257,000Source | 4,222,000Source | 4,198,000Source | 3,993,000Source | 16,984,000Source | 15,129,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 14,326,000Source | 15,507,000Source | 10,375,000Source | 15,972,000Source | 10,429,000Source | 10,267,000Source | 51,103,000Source | 69,511,000Source | 173,162,000Source | 160,020,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | -3,505,000Source | 20,181,000Source | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 13,314,000Source | 8,213,000Source |
| Interest Expense, DebtUSD | — | — | 3,932,000Source | 3,684,000Source | 3,483,000Source | 3,829,000Source | 3,696,000Source | 3,643,000Source | 15,332,000Source | 14,662,000Source | 11,941,000Source | 7,353,000Source |
| Investment Income, InterestUSD | — | — | 236,000Source | 616,000Source | 131,000Source | 230,000Source | 211,000Source | 279,000Source | 1,066,000Source | 2,602,000Source | 5,649,000Source | 2,528,000Source |
| Operating Lease, ExpenseUSD | — | — | 104,000Source | 101,000Source | 101,000Source | 101,000Source | 103,000Source | 101,000Source | 410,000Source | 394,000Source | 392,000Source | 410,000Source |
| Research and Development ExpenseUSD | — | — | 8,740,000Source | 5,101,000Source | 3,164,000Source | 10,256,000Source | 2,955,000Source | 4,554,000Source | 30,251,000Source | 30,435,000Source | 84,326,000Source | 91,239,000Source |
Filing attachments
tm2624733d2_ex99-1.htm · 8-K · 2026-10-30
Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11 BIOXCEL THERAPEUTICS, INC. et Case No. 26-11360 (TMH) al.,1 (Jointly Administered) Debtors. ORDER (A) APPROVING THE SALE OF THE DEBTORS’ ASSETS FREE AND CLEAR OF LIENS, CLAIMS, INTERESTS, AND ENCUMBRANCES, (B) APPROVING THE ASSUMPTION AND ASSIGNMENT OF EXECUTORY CONTRACTS AND UNEXPIRED LEASES, AND (C) GRANTING REL…
Read attachment ↗tm2614679d1_ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 tm2614679d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI N…
Read attachment ↗tm2612008d1_ex4-1.htm · 8-K · 2026-04-17
EX-4.1 2 tm2612008d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 EXECUTION VERSION BIOXCEL THERAPEUTICS, INC. COMMON STOCK WARRANT NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON ITS EXERCISE OR CONVERSION HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAW AND MAY NOT BE TRANSFERRED EXCEPT (I) IN ACCORDANCE WITH THE SECURITIES ACT OR SUCH APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREF…
Read attachment ↗tm2612008d1_ex4-2.htm · 8-K · 2026-04-17
EX-4.2 3 tm2612008d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 EXECUTION VERSION BIOXCEL THERAPEUTICS, INC. FOURTH Amended and Restated REGISTRATION RIGHTS AGREEMENT This FOURTH Amended and Restated Registration Rights Agreement (this “Agreement”) is made as of April 15, 2026, by and among BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), the purchasers identified on Schedule A hereto (each, a “Purchaser”) and such other Persons, if any, from time to time, that become a party he…
Read attachment ↗tm269970d1_ex99-1.htm · 8-K · 2026-03-27
EX-99.1 2 tm269970d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026 Advancing commercial and launch pl…
Read attachment ↗